Terbinafine-d3 hydrochloride(Synonyms: TDT 067-d3 hydrochloride)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白、同位素标记物，专注于信号通路和疾病研究领域。
Terbinafine-d3 hydrochloride (Synonyms: TDT 067-d3 hydrochloride)

Terbinafine-d3 (TDT 067-d3) hydrochloride 是 Terbinafine hydrochloride 的氘代物。Terbinafine hydrochloride (TDT 067hydrochloride) 是具有抗真菌感染活性的化合物。它是念珠菌属的角鲨烯环氧化酶有效的非竞争性抑制剂， Ki 值为 30 nM。Terbinafine hydrochloride 还对某些革兰氏阳性和革兰氏阴性细菌具有抗菌活性。

Terbinafine-d3 hydrochloride(Synonyms: TDT 067-d3 hydrochloride)

Terbinafine-d3 hydrochloride Chemical Structure

CAS No. : 1310012-15-7

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

Terbinafine-d3 (TDT 067-d3) hydrochloride is the deuterium labeled Terbinafine hydrochloride. Terbinafine hydrochloride (TDT 067 hydrochloride) is an antifungal medication used to treat fungal infections. It is a potent non-competitive inhibitor of squalene epoxidase from Candida with a Ki of 30 nM[1][2]. Terbinafine hydrochloride also antibacterial activity against certain Gram-positive and Gram-negative bacteria[3].

体外研究
(In Vitro)

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

330.91

Formula

C21H23D3ClN
CAS 号

1310012-15-7
中文名称

盐酸特比萘芬 d3 (盐酸盐)
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

    [2]. Ryder NS, et al. Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol. 1992 Feb;126 Suppl 39:2-8.

    [3]. Mieth H, et al. Preclinical evaluation of terbinafine in vivo. Clin Exp Dermatol. 1989 Mar;14(2):104-8.

    [4]. Ciftci E, et al. Mupirocin vs terbinafine in impetigo.Indian J Pediatr. 2002 Aug;69(8):679-82.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务